New Law Proposes to Increase Funding for Cerebral Palsy Research

This spring, Representatives Steve Cohen (D‑TN), Brian Fitzpatrick (R‑PA), and Emanuel Cleaver (D‑MO), joined by Delegate Eleanor Holmes Norton, introduced the Cerebral Palsy Research Program Authorization Act (H.R. 2178).

The bill would authorize $5 million annually to the CDC’s National Center on Birth Defects and Developmental Disabilities, establishing the very first dedicated federal research program for cerebral palsy, a condition that affects 1 in 345 U.S. children and over 1 million Americans. The reintroduction this year reflects growing congressional resolve to tackle long‑neglected CP research.

Increases in Federal Funding for Cerebral Palsy Are Overdue

Cerebral palsy stands as the most prevalent lifelong physical disability in the U.S. — yet until now, it has been absent from any dedicated federal research portfolio. Despite CP’s complexity and prevalence, more than 80 percent of cases lack a known cause. 

Compounding that, individuals with CP often face co‑occurring conditions like epilepsy, intellectual disabilities, chronic pain or vision impairment. The current investment gap has stifled progress in preventing CP, improving diagnosis, and expanding treatment.

Rep. Cohen emphasized the discrepancy: “Although cerebral palsy affects one out of every 345 children... there is no designated federal funding for research.” He warned this void has “fewer treatment options, less prevention, less education, and a lack of standards of care across lifespans.” 

At a time when federal health research is under pressure — including potential cuts to biomedicine — the Act arrives as “as needed as ever.”  For parents, advocates, and providers, its passage signals overdue recognition: CP requires federal resources that match its lifelong impact.

Which Programs Could Receive the Most Help?

If enacted, the Act would place funds under CDC’s National Center on Birth Defects and Developmental Disabilities, enabling grants and contracts for CP-specific research. Key areas poised for support include:

- Prevention & early detection – Studying prenatal, perinatal, and early-life risk factors to reduce incidence.

- Diagnostic refinement – Standardizing early identification methods, especially vital for under-served or rural communities.

- Treatment innovation – Funding trials investigating physical, occupational or speech therapies, assistive technology, and emerging interventions.

- Lifelong care models – Addressing transitions from pediatric to adult care and developing standard-of-care guidelines.

- Economic and societal impact – Analyzing the staggering lifetime costs — estimated at $13.5 billion (healthcare) and $35 billion (lost productivity) for those born in 2000 alone. 

Beyond CDC, improved surveillance could empower the Epidemiology and Surveillance Branch in tracking CP across demographics, while NIH-inspired strategic planning could follow as it once did years ago.

How Would Additional Research Funding Likely Be Used?

Experts expect the funds to be channeled through grant rounds to universities, research centers, and nonprofit partners, emphasizing:

- Clinical trials for therapies and devices – Leading-edge initiatives to test neuromodulation, robotics, or pharmaceutical strategies.

- Early intervention programs – Piloting screening efforts and parental support models to improve motor and developmental outcomes.

- Data-driven surveillance systems – Developing registries and real-world evidence platforms that track outcomes across ages and geographies.

- Education and training – Ensuring healthcare providers (and parents) receive up-to-date tools in CP care via continuing education modules.

- Economic analyses – Quantifying direct and indirect costs to guide cost-benefit assessments and policymaking.

As the Act’s text states, funding could be used “directly or through grants or contracts” to research diagnostics, treatment, mitigation, costs, surveillance, and public education.

Families of children with CP can anticipate more therapeutic options, earlier diagnosis, and a stronger evidence base to shape care throughout childhood into adulthood.

Cerebral Palsy Research on the Horizon

Beyond the Act itself, CP research is entering an innovative phase:

- Stem cell and regenerative medicine: Early-stage trials are exploring whether stem cell therapies can support motor function improvement. Though experimental, they offer future potential.

- Wearable tech and robotics: Advances in home-based robotic exoskeletons and smart wearables promise tools to support independent mobility and precise gait training.

- Genetic insights: Though over 80 percent of CP causes are currently unknown, genomic studies may uncover rare variants or prenatal risk markers, paving the way to prevention.

- Telehealth expansion: Remote physical and speech therapy platforms, accelerated during the pandemic, offer scalable care — especially for rural or medically under-served families.

- Lifespan research: As noted by Rep. Cleaver, the Act could “raise the standard of care for Americans with cerebral palsy… across the lifespan” 

This includes investigations into adult-onset complications and transition models. Collaborative networks: If the CDC’s program connects with global registries and the NIH’s strategic network, multicenter studies can rapidly scale and generate best practices.

Collectively, this growing momentum means that families can look forward to:

“Progress in advancing treatments and diagnostic practices… hope to the millions of patients, families, and loved ones” — as Rep. Cleaver said .

Final Takeaway

For parents of children with cerebral palsy, the Cerebral Palsy Research Program Authorization Act offers much-needed momentum. It’s more than a line item; it’s recognition that CP research deserves federal commitment. 

From advancing early diagnosis and therapy development to supporting lifespan care and cost-effective models, this funding could reshape what’s possible.

Now it’s up to Congress: with growing bipartisan support, families, clinicians, and advocacy groups — including the Cerebral Palsy Foundation and United Cerebral Palsy — are urging swift passage. For parents and caregivers, this moment could mark a genuine turning point: federal investment after decades of neglect, paving the way for meaningful breakthroughs and brighter futures.